

Simon van der Pol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8035288/publications.pdf>

Version: 2024-02-01

15
papers

96
citations

1651377

6
h-index

1526636

10
g-index

15
all docs

15
docs citations

15
times ranked

190
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluations of training and education interventions for improved infectious disease management in low-income and middle-income countries: a systematic literature review. <i>BMJ Open</i> , 2022, 12, e053832.	0.8	0
2	Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations. <i>Antibiotics</i> , 2022, 11, 27.	1.5	1
3	The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance. <i>Pharmacoeconomics</i> , 2022, 40, 823-833.	1.7	2
4	Efficiency of Diagnostic Testing for <i>Helicobacter pylori</i> Infections—A Systematic Review. <i>Antibiotics</i> , 2021, 10, 55.	1.5	6
5	Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. <i>European Journal of Health Economics</i> , 2021, 22, 991-999.	1.4	0
6	The tripartite insurance model (TIM): a financial incentive to prevent outbreaks of infections due to multidrug-resistant microorganisms in hospitals. <i>Clinical Microbiology and Infection</i> , 2021, 27, 665-667.	2.8	1
7	Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. <i>Pharmacoeconomics</i> , 2021, 39, 1411-1427.	1.7	8
8	Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. <i>Pharmacoeconomics</i> , 2021, 39, 1355-1363.	1.7	5
9	Author's Reply. <i>Value in Health</i> , 2020, 23, 675-676.	0.1	0
10	School health in Europe: a review of workforce expenditure across five countries. <i>BMC Health Services Research</i> , 2020, 20, 206.	0.9	8
11	Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice. <i>Value in Health</i> , 2019, 22, 1092-1101.	0.1	12
12	Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier. <i>Value in Health</i> , 2019, 22, 1119-1127.	0.1	13
13	Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review. <i>Expert Review of Vaccines</i> , 2019, 18, 897-911.	2.0	7
14	Perioperative bridging of vitamin K antagonist treatment in patients with atrial fibrillation: only a very small group of patients benefits. <i>Europace</i> , 2019, 21, 716-723.	0.7	4
15	An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands. <i>Value in Health</i> , 2017, 20, 388-396.	0.1	29